drugset / Trial / NCT06600607

Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults

NCT06600607

Phase 0 Completed 20 enrolled Latigo Biotherapeutics
RandomizedCrossoverTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test. The study will be conducted at a single center in New Zealand.

Timeline

Start
2024-10-07
Primary completion
2024-10-27
Completion
2024-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg

Indications

No indication recorded.